TYRA

Tyra Biosciences, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1863127Held by 6 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:X LINKEDIN EMAIL

Revenue FY2025

—

Net Income FY2025

$(120.0M)

EPS (Basic, as reported)

$-2.01

Net Margin FY2025

—

ROE FY2025

-46.3%

Total Equity

$259.0M

Shares Out

60M

Business description

Tyra Biosciences, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2020–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions

default rows · click any row to chart itNet income: (9) → (120)

Fiscal yearFY2020FY2021⚑FY2022FY2023FY2024FY2025

Research & development(7)(21)(43)(63)(80)(103)

General & administrative(2)(6)(16)(17)(24)(30)

Total operating expenses(9)(26)(59)(80)(104)(133)

Operating income(9)(26)(59)(80)(104)(133)

Other income (expense), net004111813

Income tax expense000000

Net income(9)(26)(55)(69)(86)(120)

EPS — basic—($1.91)($1.32)($1.62)($1.51)($2.01)

EPS — diluted—($1.91)($1.32)($1.62)($1.51)($2.01)

Shares outstanding — basic (M)—1442435760

Shares outstanding — diluted (M)—1442435760

⚑ Weighted-average shares changed ×3.00 between FY2021 and FY2022 — likely a stock split. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.